author-photo

Axel Grothey

Mayo Clinic

11

Papers

43

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

Early-onset stage II/III colorectal adenocarcinoma in the IDEA database: Treatment adherence, toxicities, and outcomes from adjuvant fluoropyrimidine and oxaliplatin.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Multitrial evaluation of longitudinal tumor measurement (TM)-based metrics for predicting overall survival (OS) using the RECIST 1.1 data warehouse.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
A randomized, double-blind, phase (Ph) III study of the irinotecan-based chemotherapy FOLFIRI plus ramucirumab (RAM) or placebo (PL) in patients (pts) with metastatic colorectal carcinoma (mCRC) progressive during or following first-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fluoropyrimidine (FP) (RAISE) (NCT01183780).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (6)
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016

2016
Show All
- Source
- Cite
- Save
Citations (1)
Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months.

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months.

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial.

2013 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (14)
Phase III randomized, placebo (PL)-controlled, double-blind study of intravenous calcium/magnesium (CaMg) to prevent oxaliplatin-induced sensory neurotoxicity (sNT), N08CB: An alliance for clinical trials in oncology study.

2013 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (11)